Ivax, Alpharma Settle Claims to Glucophage XR Generic
The suit concerned the exclusive right to sell a generic equivalent of Glucophage XR(R) tablets, marketed by Bristol-Myers Squibb Co. and indicated as adjunctive therapy in type 2 diabetes. Glucophage XR(R) tablets have brand sales of approximately $450 million annually.
Under the agreement, Alpharma has withdrawn its lawsuit in U.S. District Court for the District of Columbia against the Food and...
To view the full article, register now.